Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
July 26, 2016
Sangamo BioSciences (SGMO) gene therapy preclinical animal data
July 21, 2016
Biostage (BSTG) hires CSO
July 21, 2016
Spark Therapeutics (ONCE), Pfizer (PFE) Hemophilia Therapy gets FDA Breakthrough Status
July 20, 2016
Organovo (ONVO) Commercializes Kidney Tissue - BUY
July 18, 2016
BrainStorm (BCLI) U.S. P2 Study of NurOwn® in Patients with ALS was safe and well tolerated
July 12, 2016
Juno Therapeutics (JUNO) given FDA green light to resume trial, shares soar +26.77% or $7.44
July 11, 2016
Pluristem (PSTI) another P1 with unnamed CRO
July 11, 2016
BioLife Solutions (BLFS) inks CryoStor® supply agreement
July 11, 2016
ImmunoCellular Therapeutics (NYSEMKT: IMUC) proposes $24.2 M offering
July 7, 2016
Juno Therapeutics (JUNO) plummets as CAR-T Leukemia trial is put on hold after two deaths
July 5, 2016
Northwest Bio (NWBO) 7.4 M share offering at $0.50
June 29, 2016
UniQure (QURE) Licenses cell line and technology from Protein Sciences
June 29, 2016
Biostage (BSTG) Files for FDA Orphan Drug Designation
June 28, 2016
Cytori (CYTX) ATHENA trial data for Chronic Ischemic Cardiovascular Disease
June 27, 2016
AxoGen (AXGN) Added to Russell 2000® Index
June 27, 2016
Cytori Therapeutics (CYTX) limited Japanese approval to treat Osteoarthritis
June 24, 2016
RegMed investors’ mid-day analysis: after Brexit, repricing of risk with heightened uncertainty
June 22, 2016
Pluristem (PSTI) just another pre-clinical mouse model
June 20, 2016
Fate Therapeutics (FATE) FDA Fast Track Designation
June 20, 2016
Sangamo BioSciences, Inc. (SGMO) another gene therapy IND
June 20, 2016
Kite Pharma, Inc. (KITE) and National Cancer Institute (NCI) initiate HPV research and clinical development projects
June 16, 2016
BioTime (NYSEMKT: BTX) prices 7.322 M share offering - $2.39
June 14, 2016
Mesoblast Limited (MESO) damage accessed, the aftermath …
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.